ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0676

Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert

Lesley Jackson1, Narender Annapureddy2, Kenneth Saag1, James Booth3, Giovanna Rosas1, Jeffrey Foster1, Amy Mudano1, Dongmei Sun4, John Osborne1, Tim Bongartz5, Erik Hess5, Colleen Lawrence6, Leah Dunkel6 and Maria I. Danila1, 1University of Alabama at Birmingham, Birmingham, AL, 2Vanderbilt University Medical Center, Nashville, TN, 3Department of Emergency Medicine, University of Alabama School of Medicine, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 5Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, 6Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2021

Keywords: Access to care, Disparities, gout, informatics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients with acute gout are frequently treated in emergency departments (ED) and represent a typically underserved and understudied population. A key limitation of conducting gout research in the ED is the timely ability to identify potential gout patients during an ED encounter. The objective of our study was to develop a multi-criteria electronic medical record (EMR)-based gout flare alert for acute gout flares and determine its diagnostic properties for gout flare identification among ED patients.

Methods: The alert used EMR data entered by ED nursing staff and the medical problem list. The alert was triggered by: the term ‘gout’ preceding the past medical history in the chief complaint field, the term ‘gout’ and a musculoskeletal problem in the chief complaint, or the term ‘gout’ in the problem list and a musculoskeletal chief complaint (Table 1). We validated the presence/absence of gout through manual EMR review using adjudicated expert consensus (assessed with kappa coefficient) as the gold standard. We abstracted ED cases of possible gout patients in whom gout flare symptoms were not documented but who might have had gout based on other clinical parameters (e.g., those with an ICD-10 code for gout at the ED visit (M10.X), those who had an arthrocentesis performed in the ED and had an order placed for uric acid crystal analysis in the synovial fluid, and any patient who had an order for colchicine during their ED visit) to identify possible false negative cases.

Results: From January 1 to February 1, 2020, there were 38 patients with acute gout flare identified by the components of the gout flare alert and an additional 93 were identified as potentially having an acute gout flare and were included in the analysis of the alert characteristics. The positive predictive value (PPV) of the alert was 42% (95% CI [26 – 58%]) and the negative predictive value (NPV) was 93% (95% CI [87 – 98%]). The gout flare alert had a sensitivity of 70% (95% CI [51 – 88%]) and specificity of 80% (95% CI [72 – 87%]) (Table 2). Prevalence of a true gout flare was 16/38 (42%) among patients in whom the gout flare alert fired and 7/93 (8%) among patients in whom the gout flare alert did not fire. The kappa coefficient for agreement between the consensus expert determination of acute flare and the documented ED diagnosis of flare was 0.9. A second alert validation procedure occurred between October 24, 2020 to November 24, 2020. During this period, the gout flare alert had a lower overall PPV of 24% likely due to fewer gout flare cases seen in the ED due to the COVID-19 surge in our region.

Conclusion: We developed, refined, and validated a multi-component EMR gout flare alert with reasonable predictive properties to detect patients with an acute gout flare during the ED visit. This screening tool achieves good sensitivity and NPV, which preferentially increases the number of detected cases and allows the ED team to rule out false positives with secondary data. An automated EMR alert may help identify patients with acute gout flare in real time upon presentation to the ED. These patients may be approached for study recruitment or quality improvement strategies beyond the standard of care.

Table 1. Key phrases and parameters used to identify acute gout flare in the gout flare alert.
*Past medical history included the following terms (not case-sensitive): pmh, pmhx, hx, past medical history.
†Pain locations included the following musculoskeletal sites: ankle, arm, elbow, leg, feet, finger, foot, hand, hip, knee, shoulder, thumb, toe, wrist.

Table 2. Test characteristics of the electronic medical record gout flare alert system and the individual components of the algorithm.
*listed are each of three components of the overall alert algorithm.


Disclosures: L. Jackson, None; N. Annapureddy, GSK, 2; K. Saag, Arthrosi, 2, Atom Bioscience, 2, Horizon Therapeutics, 2, 5, LG Pharma, 2, Mallinkrodt, 2, SOBI, 2, 5, Takeda, 2, Shanton, 5; J. Booth, None; G. Rosas, None; J. Foster, None; A. Mudano, None; D. Sun, None; J. Osborne, None; T. Bongartz, None; E. Hess, None; C. Lawrence, None; L. Dunkel, None; M. Danila, Boehringer Ingelheim, 5, Amgen, 1, Amgen, 5, AbbVie, 1, Pfizer, 5, Pfizer, 11, Horizon, 5, Novartis, 1, WebMD, 12, writer.

To cite this abstract in AMA style:

Jackson L, Annapureddy N, Saag K, Booth J, Rosas G, Foster J, Mudano A, Sun D, Osborne J, Bongartz T, Hess E, Lawrence C, Dunkel L, Danila M. Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/development-refinement-and-validation-of-an-emergency-department-gout-flare-electronic-medical-record-alert/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-refinement-and-validation-of-an-emergency-department-gout-flare-electronic-medical-record-alert/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology